

# XXII LIPID MEETING LEIPZIG

December 9–11, 2021

Virtual conference



## PROGRAM


[www.lipidmeeting.de](http://www.lipidmeeting.de)

## TABLE OF CONTENTS



## small dense LDL

*Für eine verbesserte kardiovaskuläre Risikoabschätzung*



Auch bei unauffälligen LDL-Cholesterinwerten kann durch die zusätzliche Bestimmung von small dense LDL das kardiovaskuläre Risiko erheblich besser klassifiziert werden.

Small dense LDL vervollständigt das Lipid-Portfolio von Roche Diagnostics und schafft zielgenaue Risikoprofile.

---

Find out more on  
[www.roche.de/lipidparameter](http://www.roche.de/lipidparameter)




cobas®

- 5 Greeting
- 6 Organizer
- 10 2<sup>nd</sup> Epigenetics Symposium
- 11 Program
- 15 Poster
- 16 Symposia
- 17 Supporters
- 18 Quiz

# 8. MITTELDEUTSCHE LABORKONFERENZ



05.–06. Mai 2022  
**congress centrum**  
**weimarthalle**



## GREETING

December 9–11, 2021

The XXII Lipid Meeting Leipzig will be held December 09-11th, 2021 in Leipzig.

Due to the unusual circumstances with the ongoing Covid-19 pandemic the meeting must be virtually this year. While we will miss the personal interactions and the live scientific discussions, not only in the meeting rooms, but also in between in the hallways and during social events, we are confident that – with the great program and excellent contributions – we will have a great scientific meeting!

Since its foundation more than twenty years ago, this meeting in the heart of Germany has developed into an established forum for scientific discussion and interdisciplinary collaboration in all relevant areas of lipid metabolism and diseases caused by metabolic disorders.

The international XXIIIth Lipid Meeting Leipzig 2021 will give a high level update on genetic studies of lipid metabolism and lipid related diseases. The advent of new therapeutic developments targeting lipid disorders and the increasing awareness about the relevance of lipids and their metabolites illustrates the relevance of this meeting. We will discuss timely and evolving topics related, among others, to fatty liver disease, single cell analyses and lipidomics, early priming of chronic disease trajectories and disease resolution. These topics will be presented and discussed by internationally renowned experts.

The Lipid Meeting is open for all physicians, scientists and students interested in the fascinating field lipid function in medicine and physiology. It brings together an international group of participants from all career levels and from various scientific and medical disciplines to present cutting-edge research in a collegial atmosphere.

We hope to offer you an interesting and scientifically exiting meeting and look forward to welcoming you in Leipzig.

A handwritten signature in black ink, appearing to read "Uta Ceglarek".

PROF. DR. UTA CEGLAREK

Institute of Laboratory Medicine,  
Clinical Chemistry and Molecular Diagnostics,  
Medical Faculty

A handwritten signature in black ink, appearing to read "Berend Isermann".

PROF. DR. BEREND ISERMANN

Institute of Laboratory Medicine,  
Clinical Chemistry and Molecular Diagnostics,  
Medical Faculty

A handwritten signature in black ink, appearing to read "Ulrich Laufs".

PROF. DR. ULRICH LAUF

Clinic and Polyclinic for Cardiology, University  
Hospital Leipzig

A handwritten signature in black ink, appearing to read "Matthias Blüher".

PROF. DR. MATTHIAS BLÜHER

Helmholtz Institute for Metabolism, Obesity and Vascular  
Research (HI-MAG)  
Helmholtz Center Munich at the University of Leipzig and  
the University Hospital Leipzig AÖR

## SCIENTIFIC COMMITTEE

Prof. Dr. Uta Ceglarek

Prof. Dr. Berend Isermann

Institute of Laboratory Medicine, Clinical Chemistry and Molecular Diagnostics, Medical Faculty University Hospital Leipzig AöR

Prof. Dr. Ulrich Laufs

Clinic and Polyclinic for Cardiology, University Hospital Leipzig AöR

Prof. Dr. Matthias Blüher

Helmholtz Center Munich at the University of Leipzig and the University Hospital Leipzig AöR

Institute of Laboratory Medicine

Clinical Chemistry and Molecular Diagnostics  
Universitätsklinikum Leipzig AöR

📍 Liebigstraße 27

D-04103 Leipzig

📞 +49 341 97 22-200

✉ katja.seidel@medizin.uni-leipzig.de

🌐 www.lipidmeeting.de

## CONFERENCE OFFICE

event lab. GmbH

📍 Richard-Lehmann-Str. 12

D-04275 Leipzig

🌐 www.eventlab.org

## SUPPORTED BY

Deutsche Forschungsgemeinschaft  
(DFG)



Deutsche Gesellschaft für Klinische  
Chemie und Laboratoriumsmedizin  
e.V. (DGKL)



## LIVESTREAM | QUESTIONS AND ANSWERS ABOUT YOUR VIRTUAL PARTICIPATION

## WHERE DO I FIND MY LOGIN DATA?

You received an email with your access data on December 8, 2021.

These consist of the link to the livestream, your last name and your personal passcode. Please contact us if there are any questions about this.

WHAT ARE THE TECHNICAL REQUIREMENTS FOR PARTICIPATION  
IN THE VIRTUAL CONGRESS?

You need a PC, laptop, tablet, or smartphone, the latest browser version - preferably Google Chrome - and access to the internet. For optimized transmission quality, we recommend using a wired LAN connection.

Closing inactive tabs in the browser can help to improve transmission quality. The browser "Internet Explorer" is outdated and therefore not suitable for participation in the digital congress.

If you have problems with the sound, it may be helpful to use headphones and / or use a different browser (e.g. Chrome, Firefox or Microsoft Edge).

## HOW CAN I ASK MY QUESTIONS TO THE SPEAKERS?

Use the interaction tool slido embedded next to the livestream window and write your questions. The questions will be collected and answered live during the discussion.

Alternatively, you can go to <https://slido.com> and enter the congress hashtag #LIPID1 of Livestream room 1 and #LIPID2 for Livestream room 2.

This is especially helpful if you are watching the livestream in full screen mode, and retrieve slido on a separate device.

## I NEED TECHNICAL SUPPORT. WHO IS MY CONTACT PERSON?

Please contact our digital counter by phone or email.

Friday, December 10, 2021 07:30 am–07:00 pm

Saturday, December 11, 2021 08:00 am–02:30 pm

✉ lipidmeeting@eventlab.org

📞 +49 (0) 341 30 88 84 89

## GENERAL INFORMATION

### HOW DO I WATCH THE LECTURES AFTER THE CONGRESS?

The presentations will be available in a media library approx. one week after the congress. We will inform you about this by email.

### HOW DO I RECEIVE CONTINUING EDUCATION CREDITS AND MY CERTIFICATE OF ATTENDANCE?

Your attendance is recorded digitally by logging in every day with your personalized access data. You will receive your certificate of attendance by email after the congress. Please allow us one week for this.

The certification of the event has been applied at the Medical Association of Saxony as follows:

- ⌚ Friday, December 10, 2021 | 10 points
- ⌚ Saturday, December 11, 2021 | 4 points

### HOW DO I FIND OUT ABOUT THIS YEAR'S SUPPORTERS?

Also with a virtual participation, you have the opportunity to get to know our supporters and find out what's new. To do so, be sure to check out our virtual supporter platform.

At this point we would like to thank all our supporters.

### WHERE DO I FIND THE POSTER EXHIBITION?

On the livestream page you can click on 'Poster exhibition' to have a look at all posters.

## Medical Information



Novartis Pharma GmbH  
Roonstraße 25  
90429 Nürnberg

# 2<sup>ND</sup> EPIGENETICS SYMPOSIUM

## DECEMBER 9, 2021

December 9–11, 2021

Metabolic diseases such as obesity and type 2 diabetes are of a complex nature making the identification of factors driving their development and progression highly challenging. During the past two decades, big genome-wide studies successfully identified genes involved in the pathophysiology of metabolic diseases. However, only a small proportion of the heritability can be explained so far. Therefore, focusing on additional factors such as epigenetics and the environmental impact can help untangle the complexity of metabolic diseases and open novel views on their mechanisms and pathways. Thus, understanding how environmental, genetic and epigenetic factors interact and regulate metabolism is of upmost importance.

The Epigenetics symposium aims to address and discuss precisely these questions. For instance, beside genetic risk factors, what can we learn from the genetic architecture, non-coding factors and epigenetic modifications in obesity and related diseases? How are environmental factors involved in gene regulation? And how can we translate this knowledge into diagnosis, prognosis up to prevention and treatment strategies? Having an exclusive list of renowned speakers, the symposium aims to bring cutting edge knowledge and especially invites young enthusiastic scientists to join this meeting and contribute to fruitful discussions.

### Thursday, December 9, 2021

Session 1	
01:00– 01:30	Epigenetic determinants of disease incidence Andrew Pospisilik (Van Andel Institute, USA)
01:30– 02:00	DNA methylation linked to type 2 diabetes and circulating lipids Charlotte Ling (Lund, Sweden)
02:00– 02:30	Early life exposures and precision diabetes prevention Paul Franks (Lund University, Sweden/Novo Nordisk Foundation, Denmark)
02:30– 03:00	Break
Session 2	
03:00– 03:30	The role of CBP/p300 in global acetylation and transcriptional regulation Chuna Choudhary (University Copenhagen, Denmark)
03:30– 04:00	Decoding chromatin states by proteomic profiling of modification-dependent nucleosome readers Till Bartke (Helmholtz Munich, Germany)
04:00– 04:30	Interplay between metabolism and epigenetics in health and disease Bilal Sheikh (Helmholtz Leipzig, Germany)

# PROGRAM

### Friday, December 10, 2021

08:30– 10:00	Plenary Session 1 - Organ specific lipid handling Chairs: J. Thiery, Kiel   B. Isermann, Leipzig Livestream Room 1
08:30– 09:00	Lipid handling by endothelial cells of thermogenic adipose tissues J. Heeren, Hamburg
09:00– 09:30	Lipoproteins in chronic kidney disease T. Speer, Homburg/Saar
09:30– 10:00	Metabolic liver disease in diabetes - From mechanisms to clinical trials S. Herzig, Neuherberg
10:00– 10:15	Coffee Break
10:15– 12:45	Basic research - Liver and Lipid Metabolism Translation and clinical application - New approaches to better patient stratification
10:15– 11:20	WS 1: Lipids and liver cell biochemistry Chairs: T. Schöneberg, Leipzig   M. Matz-Soja, Leipzig Livestream Room 1
10:15– 10:20	Remodelling of the proteasome as a key feature of brown adipocyte differentiation and cold adaptation N. Willemse, Munich
10:20– 10:40	Monitoring lipid localisation and molecular identity in cellular transport processes A. Nadler, Dresden
10:40– 11:00	Structural insights into EHD-mediated membrane remodelling and its role in regulating cellular fatty acid uptake O. Daumke, Berlin
11:00– 11:20	Quality control of the mitochondrial proteome (including regulation of lipid metabolism) T. Becker, Bonn
11:20– 11:40	Short Break
11:40– 12:45	WS 3: Lipid metabolism and NASH Chairs: T. Kaiser, Leipzig   J. Wiegand, Leipzig Livestream Room 1
11:40– 11:45	The impact of cholesterol lowering drugs on metabolism and epigenetics A. Rose, Leipzig
	WS 4: Diet, lipid metabolism and diseases Chairs: R. Burkhardt, Regensburg   A. von Eckardstein, Zürich Livestream Room 2
	Adipocyte-p53 shapes adipose tissue plasticity upon intermittent fasting in obese mice I. Reinisch, Graz

11:45– 12:05	Hepatic lipid droplet homeostasis and fatty liver disease ⌚ N. Krahmer, Neuherberg	Lipidomics for patient stratification ⌚ M. Haid, Neuherberg
12:05– 12:25	Cell-based strategies against a fatty liver ⌚ B. Christ, Leipzig	Can we treat metabolic diseases with diet? ⌚ M. Blüher, Leipzig
12:25– 12:45	Macrophages in obesity and non-alcoholic fatty liver disease: Crosstalk with metabolism ⌚ F. Tacke, Berlin	Effects of Diet-Modulated Autologous Fecal Microbiota Transplantation on Weight Regain ⌚ E. Rinott, Beer Sheva
12:45– 02:30	⌚ Lunch Break	
01:15– 02:15	Satellite Symposia supported by Novartis	Satellite Symposia supported by 10x Genomics
02:30– 04:00	Plenary Session 2 - lipidmetabolism in cardiovascular disease ⌚ Chairs: U. Laufs, Leipzig   M. Stumvoll, Leipzig ⌚ Livestream Room 1	
02:30– 03:00	Myeloid cells in cardiovascular health ⌚ M. Nahrendorf, Boston	
03:00– 03:30	Platelet lipidomics, atherosclerosis, coronary artery disease ⌚ M. Gawaz, Tübingen	
03:30– 04:00	Inflammation and atherosclerosis - new mechanisms ⌚ P. Libby, Boston	
04:00– 04:30	⌚ Coffee Break	
04:30– 05:10	WS 5: Mechanisms of atherosclerosis ⌚ Chairs: S. Herzig, Neuherberg   J.N. Boeckel, Leipzig ⌚ Livestream Room 1	WS 6: Adipose tissue – more than a sink for lipids ⌚ Chairs: M. Blüher, Leipzig   B. Sheikh, Leipzig ⌚ Livestream Room 2
04:30– 04:50	The role of red cell eNOS signaling in blood / vessel interactions and systemic hemodynamics ⌚ M. Cortese-Krott, Düsseldorf	Single cell approaches to understand adipose tissue function ⌚ S. Mandrup, Odense
04:50– 05:10	Immaculate conception or planned pregnancy – the birth of macrophages in atherosomatous plaques ⌚ I. Hilgendorf, Freiburg	Adipose tissue at the cross roads of metabolism and inflammation ⌚ J. Ferno, Bergen
05:10– 06:25	Poster Session ⌚ Chairs: P. Büttner   M. Matz-Soja   K. Shahzad   O. Tiebel   J.-N. Boeckel	
<b>Saturday, December 11, 2021</b>		
09:00– 10:00	WS 7: Macrophage metabolism and function ⌚ Chairs: P. Mirtschink, Dresden   U. Wagner, Leipzig ⌚ Livestream Room 1	WS 8: Lipids - from analyses to new clinical approaches ⌚ Chairs: J. Ferno, Bergen   P. Kovacs, Leipzig ⌚ Livestream Room 2

09:00– 09:20	The PI3K pathway preserves metabolic health through MARCO-dependent lipid uptake by adipose tissue macrophages ⌚ G. Schabbauer, Vienna	Human „lipidome atlas“ for adipose tissue ⌚ M. Fedorova, Dresden
09:20– 09:40	Developmental programming of Kupffer cells by maternal obesity ⌚ E. Mass, Amsterdam	Novel mechanisms of adipocyte proteostasis and inflammation ⌚ A. Bartelt, Munich
09:40– 10:00	Macrophage ATP citrate lyase deficiency stabilizes atherosclerotic plaques ⌚ J. van den Bossche, Amsterdam	TG-rich lipoproteins – pathophysiology and novel treatments ⌚ U. Laufs, Leipzig
10:00– 10:30	⌚ Coffee Break	
10:30– 11:30	Plenary Session 3 - New insights into lipidmetabolism and associated diseases ⌚ Chairs: O. Tiebel, Dresden   H. Thiele, Leipzig ⌚ Livestream Room 1	
10:30– 10:50	Novel mechanisms of LDL receptor regulation ⌚ A. von Eckardstein, Zürich	
10:50– 11:10	Neue Mechanismen der Atherosklerose ⌚ C. Weber, Munich	
11:10– 11:30	snRNA-seq reveals a subpopulation of adipocytes that regulates thermogenesis ⌚ C. Wolfrum, Schwerzenbach	
11:30– 01:00	⌚ Lunch Break	
11:45– 12:45	Satellite Symposia supported by Sanofi-Aventis Deutschland GmbH	
01:00– 02:05	WS 9: Platelets and lipids - topic 13 ⌚ Chairs: M. Gawaz, Tübingen   A. Sickmann, Dortmund ⌚ Livestream Room 1	WS 10: Fetal programming of adult diseases ⌚ Chairs: A. Zenclussen, Leipzig   S. Kohli, Leipzig ⌚ Livestream Room 2
01:00– 01:05	Meta-GWAS of PCSK9 levels detects two novel loci at APOB and TM6SF2 ⌚ J. Pott, Leipzig	Meta-GWAS of PCSK9 levels detects two novel loci at APOB and TM6SF2 ⌚ D. Haas
01:05– 01:25	Platelets, pro-resoluting lipid mediatory, liver disease ⌚ A. Körner, Tübingen	Maternal lipid metabolism-reprogramming ⌚ M. Wolfgang, Baltimore
01:25– 01:45	Probing the platelet lipidome from lipid structure to function ⌚ R. Ahrends, Vienna	Deciphering the role of the placenta in the developmental programming of diabetes and obesity risk ⌚ A. Sferruzzi-Perri, Cambridge
01:45– 02:05	Platelets, wound healing, metabolic reprogramming ⌚ A.-M. Rodriguez, Créteil cedex	Perinatal programming, epigenetics, and long term consequences for lipid metabolism ⌚ T. Plösch, Groningen
02:05– 02:15	Farewell and announcement of the winners of the poster awards	

# PRALUENT® IST ZURÜCK

Jetzt auch mit monatlicher Dosierung\*  
in einem Fertigpen



MACHEN SIE PRALUENT®  
ZU IHRER WAHL



Sie wollen dazu mehr erfahren?  
Dann besuchen Sie unsere Website.  
[www.pcsk9-inhibitor.de](http://www.pcsk9-inhibitor.de)

PRALUENT® ist angezeigt bei Erwachsenen mit bestehender atherosklerotischer kardiovaskulärer Erkrankung zur Reduktion des kardiovaskulären Risikos durch Verringerung der LDL-C-Werte zusätzlich zur Korrektur anderer Risikofaktoren.

\* Subkutane Injektion 300 mg alle vier Wochen (monatlich).

Praluent® 75 mg Injektionslösung in einem Fertigpen · Praluent® 150 mg Injektionslösung in einem Fertigpen · Praluent® 75 mg Injektionslösung in einer Fertigspritze · Praluent® 150 mg Injektionslösung in einer Fertigspritze · Praluent® 300 mg Injektionslösung in einem Fertigpen

**Wirkstoff:** Alirocumab. **Zusammens.:** Arzneil. wirks. Bestandt.: Fertigpen/-spritze mit 75/150 mg Alirocumab in 1ml Lösung; Fertigen mit 300 mg Alirocumab in 2 ml Lösung. Sonst. Bestandt.: Histidin, Saccharose, Polysorbit 20, H2O f. Injektionszw. **Anw.-geb.:** Primäre Hypercholesterinämie u. gemischte Dyslipidämie: Begleitend zu einer Diät b. primärer Hypercholesterinämie o. gemischt. Dyslipidämie in Komb. m. Statin od. Statin u. ander. Lipidsenk. Therapien b. Pat., die m. Statinther. LDL-C-Zielwerte nicht erreich. od. als Monotherap. od. in Komb. m. Lipidsenk. Therapien b. Pat mit Statin-Unverträgl. od. bei Statin-Kontraindik. **Bestehende atherosklerotische kardiovaskuläre Erkrankung:** Bei Erw. mit bestehender atherosklerotischer kardiovaskulärer Erkrank. zur Reduktion des kardiovaskulären Risikos durch Verringerung der LDL-C-Werte zusätzlich zur Korrektur anderer Risikofakt.: in Komb. m. einer max. verträgl. Statin-Therapie mit od. ohne ander. Lipidsenk. Therapieprinzipien od. als Monotherap. od. in Komb. mit ander. Lipidsenk. Therapieprinzipien bei Pat. mit einer Statin-Unverträgl. od. wenn Statine Kontraindiziert sind. **Gegenanz.:** Überempf. geg. Wirkstoff od. sonst. Bestandt. **Nebenw.:** Immunsyst.: Selten: Überempf. Hypersensibilitätsvaskulitis. Atemw./Brust/Mediast.: Häufig: klin. Zeichen u. Sympt. i. Bereich d. oberen Atemwege. Haut/Unterhautzellgew.: Häufig: Pruritus; selten: Urtikaria, nummul. Ekzem; nicht bek.: Angioödem Allgem./Beschw. a. Verabreichungsort: Häufig: Reakt. a. d. Injektionsstelle; nicht bek.: Grippeähn. Erkr. **Verschreibungspflichtig.** Pharmazeutischer Unternehmer: sanofi-aventis groupe, 54, rue La Boétie, 75008 Paris, Frankreich. Örtlicher Vertreter d. Zulassungsinhabers: Sanofi-Aventis Deutschland GmbH, D-65926 Frankfurt am Main. **Stand:** Dezember 2020



The poster sessions will take place on Friday, December 10, 2021  
from 5:10–6:25 pm.

In advance, the program committee has already selected the best 6 posters.

These will be available for voting the best three posters until Saturday, December 11, 2021. Each participant can cast one vote. The announcement of the winners will be made during the farewell on Saturday at about 2:05 pm.

The first 3 winners will receive prize money totaling €2,500.

#### Nominees for poster prize

Adipocyte-p53 shapes adipose tissue plasticity upon intermittent fasting in obese mice

I. Reinisch, Graz

Characterization of Contact Sites between Lipid Droplets and Mitochondria during Thermogenesis in Brown Adipose Tissue by Protein Correlation Profiling

D. Haas, Munich

Meta-GWAS of PCSK9 levels detects two novel loci at APOB and TM6SF2

J. Pott, Leipzig

Remodelling of the proteasome as a key feature of brown adipocyte differentiation and cold adaptation

N. Willemsen, Munich

Microbiome-derived Trimethylamine N-Oxide is not independently associated with Stable Atherosclerotic Cardiovascular Disease but with Diabetes Mellitus

C. Ringel, Leipzig

The impact of cholesterol lowering drugs on metabolism and epigenetics

A. Rose, Leipzig

# SYMPOSIA

December 9–11, 2021

## Friday, December 10, 2021

01:15–  
02:15 Novartis | modern lipid management – today and in the future  
Chair: U. Laufs, Leipzig

- From oral – towards nucleic acid-based injection – the evolution in lipid therapy.  
– O. Weingärtner, Jena
- siRNA against PCSK9 as novel lipid lowering drug – a new door opens for practice  
– first experience and perspectives... – U. Schatz, Dresden



01:15–  
02:15 10x Genomics | Uncover the hidden complexities of biology with single cell and spatial solutions  
L. Burkhardt, Leiden



The vast complexities of biology require approaches to build a complete picture, starting from single cells to tissues and beyond. At 10x Genomics, we provide single cell and spatial solutions that enable researchers to address complex questions that have evaded previous technologies. See how 10x Genomics is helping researchers uncover molecular insights, investigate the adaptive immune system, detect novel biomarkers, map the epigenetic landscape cell by cell as well as assess gene expression with morphological context. Join us for this seminar to learn how Chromium Single Cell and Visium Spatial solutions from 10x Genomics can help you push the boundaries of your research.

## Saturday, December 11, 2021

11:45–  
12:45 Sanofi | Heart and Lipids – Focussing on cardiovascular risk reduction  
Chair: J. Thiery, Kiel



- Improvement in cardiovascular risk reduction by treatment with PCSK9 inhibitors – which patients benefit the most? – U. Laufs, Leipzig
- Cardiovascular High Risk Patients – still a long way to go! – H. Schunkert, Munich

# SUPPORTERS

## WE THANK OUR SUPPORTERS



The financial support of the supporters is disclosed on the conference homepage under the following link: [www.lipidmeeting.de/virtual-exhibition](http://www.lipidmeeting.de/virtual-exhibition)

## QUIZ

**HINT:** We are looking for animals.

**I.** I have no sword, I have no spear, yet rule  
a horde which many fear, my soldiers fight  
with wicked sting, I rule with might, yet am  
no king. What am I?

---

**II.** Stealthy as a shadow in the dead of  
night, cunning but affectionate if given a  
bite. Never owned but often loved. At my  
sport considered cruel but that's because  
you never know me at all. What am I?

---

**III.** What kind of can never needs a  
can-opener?

---

**IV.** A guy always in armor,  
But never been at war.  
Sleeps in armor, walks in armor.  
Slow he is, but heavy is the armor.  
No sword, no bow, spear.  
Who is it?

---

**V.** What peels like an onion but still  
remains whole?

---



# Biology at true resolution

Resolve biological complexities  
with single cell and spatial solutions

#### Chromium Single Cell Solutions

Single Cell Gene Expression  
Single Cell CRISPR Screening  
Single Cell Immune Profiling  
Single Cell Antigen Specificity  
Single Cell Multiomic Cytometry  
Single Cell ATAC  
Single Cell Multiome ATAC + Gene Expression  
Targeted Gene Expression

#### Visium Spatial Solutions

Spatial Gene Expression  
Spatial Proteomics  
Targeted Gene Expression

Join the **10x Genomics** symposium for an interesting talk!

*"Uncover the hidden complexities of biology with single cell and spatial solutions"*

Lia Burkhardt PhD | Science & Technology Advisor at 10x Genomics

Friday, December 10, 2021 | 1:15 PM - 2:15 PM CET



Triglyceride reduzieren –  
Möglichkeiten eröffnen

## EINZIG ZUGELASSENE MEDIKAMENTÖSE THERAPIE DES FAMILIÄREN CHYLOMIKRONÄMIE SYNDROMS<sup>1</sup> (FCS)

- Signifikante Reduktion der Triglyceride<sup>1</sup>  
- Reduziert die Häufigkeit von Pankreatitiden<sup>1</sup>



Waylivra® ist eine eingetragene Marke von Akcea Therapeutics, Inc. Entdeckt und entwickelt von Ionis Pharmaceuticals und vertrieben im Rahmen einer Vereinbarung mit Akcea Therapeutics.  
488-WAY-DA(D)-1121-V01

\* Neben einer Diät

1 Fachinformation Waylivra® (Volanesorsen) Stand Februar 2021

### FACHKURZINFORMATION DEUTSCHLAND

Waylivra 285 mg Injektionslösung in einer Fertigspritze. ▼ Dieses Arzneimittel unterliegt einer zusätzlichen Überwachung.

**QUALITATIVE UND QUANTITATIVE ZUSAMMENSETZUNG: Wirkstoff:** Volanesorsen. Jede Einzeldosis-Fertigspritze enth. 285 mg Volanesorsen in 1,5 ml Lösung · **Sonst. Bestandt.:** Natriumhydroxid (zur pH-Einstellung), Salzsäure (zur pH-Einstellung), Wasser f. Injektionszwecke. **Wirkstoffgruppe:** Mittel, die den Lipidstoffwechsel beeinflussen; andere Mittel, die den Lipidstoffwechsel beeinflussen. ATC-Code: C10AX18 · **ANWENDUNGSGEBIETE:** f. d. unterstützende Behandlung neben e. Diät b. erwachsenen Patienten mit genetisch bestätigter Familiär Chylokiemronämie Syndrom (FCS) und e. hohen Risiko f. Pankreatitis, bei d. das Ansprechen auf e. Diät und e. triglyceridenkende Therapie unzureichend war · **GEGENANZEIGEN:** Überempf. gegen den Wirkstoff o. einen d. sonst. Bestandt., chronische o. ursächlich unklare Thrombozytopenie. Bei Thrombozytopenie (Thrombozyten < 140 × 10<sup>9</sup>/l) darf d. Therapie nicht eingeleitet werden. **NEBENWIRKUNGEN:** Sehr häufig: Thrombozytopenie, a. d. Injektionsstelle: Hautrotung, Schmerzen, Blässe, Schwellung, Juckreiz, Hautverhartung, Verhartung, blauer Fleck, Odem; Thrombozytentzahl vermind. **Haut:** Leukopenie; Eosinophilie; immunthrombozytopenische Purpura; spontane Hämatombildung; Impfreakt.; Hypersensitivität; serumkrankheitsähnliche Reakt.; Diabetes mell.; Schlaflosigkeit; Kopfschm.; Hypästhesie; Präsynkopie; retinale Migräne; Synkope; Schwindgefühl; Tremor; konjunktivale Blutung; Verschwommensehen; Hämatombildung; Hypertonie; Blutung; Hitzezwellungen; Epistaxis; Husten; Dyspnoe; verstopfte Nase; Pharynxödem; Giemen; Übelkeit; Diarröh; Mundtrockneheit; Zahnfleischbluten; Mundschleimhautblutung; Ohrspeicheldrusenvergrößerung; Erbrechen; Bauchschm.; Blähungen; Dyspepsie; Gingiveschwellung; Erythem; Pruritus; Urtikaria; verstärktes Schwitzen; Hautausschlag; Petechien; Ekchymosen; Nachtenschweiß; Papel; Hypertrophie d. Haut; Gesichtsschwellung; Myalgien; Arthralgien; Gliederschm.; Arthritis; Rückenschm.; muskuloskelettale Schm.; Nackenschm.; Muskelkrämpfe; Gelenksteife; Myositis; Kieferschm.; Polymyalgia rheumatica; Hamatuirie; Proteinurie; Asthenie; Abgeschlagenheit; a. d. Injektionsstelle: Hämatom, Reaktion, Urtikaria, trockene Haut; Blutung; Hypästhesie; Bläschenbildung; Missemmpfindungen; Entzündung; Gewebevermehrung; Parästhesien; Schorf; Papel; Überwärmung d. Injektionsstelle; Schüttelfrost; Fieber; Unwohlsein; Hitzegefühl; grippeähnliches Krankheitsbild; Schmerzen; Odem; nichtkardiale Thoraxschmerzen; Blutung a. einer Gefäßpunktionsstelle; renale Kreatinin-Clearance; Leukozytentzahl; Hämoglobin vermind.; Serumkreatinin; Serumharnstoff; Transaminasen; Leberenzymwert; INR erhöht; Kontusion · **STAND D. INFORMATION: Mai 2021 · INHABER DER ZULASSUNG:** Akcea Therapeutics Ireland Ltd., Regus House, Harcourt Centre, Harcourt Road, Dublin 2, Irland · **VERSCHREIBUNGSPFLICHTIG:** Örtlicher Vertreter Swedish Orphan Biovitrum GmbH, Fraunhoferstr. 9a, 82152 Martinsried, Deutschland; Telefon +49 89 5506676-0, Fax +49 89 5506676-26, E-Mail: mailde@sobi.com, Internet: www.sobi-deutschland.de Weitere Informationen entnehmen Sie bitte der Fachinformation von Waylivra 285 mg Injektionslösung in einer Fertigspritze.

### FACHKURZINFORMATION ÖSTERREICH

▼ Dieses Arzneimittel unterliegt einer zusätzlichen Überwachung. Waylivra 285 mg Injektionslösung in einer Fertigspritze.

**QUALITATIVE UND QUANTITATIVE ZUSAMMENSETZUNG:** Jede Einzeldosis-Fertigspritze enthält 285 mg Volanesorsen in 15 ml Lösung · **Liste der sonstigen Bestandteile:** Natriumhydroxid (zur pH-Einstellung), Salzsäure (zur pH-Einstellung), Wasser für Injektionszwecke · **ANWENDUNGSGEBIETE:** Waylivra ist angezeigt für die unterstützende Behandlung neben einer Diät bei erwachsenen Patienten mit genetisch bestätigtem Familiären Chylokiemronämie Syndrom (FCS) und einem hohen Risiko für Pankreatitis, bei denen das Ansprechen auf eine Diät und eine triglyceridenkende Therapie unzureichend war. **GEGENANZEIGEN:** Überempfindlichkeit gegen den Wirkstoff oder einen der sonstigen Bestandteile. Chronische oder ursächlich unklare Thrombozytopenie. Bei Thrombozytopenie (Thrombozytenzahl < 140 × 10<sup>9</sup>/l) darf die Therapie nicht eingeleitet werden · **PHARMAKOTHERAPEUTISCHE GRUPPE:** Mittel, die den Lipidstoffwechsel beeinflussen; andere Mittel, die den Lipidstoffwechsel beeinflussen; ATC-Code: C10AX18 · **VERSCHREIBUNGSPFLICHT/APOTHEKENPFLICHT:** Rezept- und apothekepflichtig, wiederholte Abgabe verboten · **INHABER DER ZULASSUNG:** Akcea Therapeutics Ireland Ltd., Regus House, Harcourt Centre, Harcourt Road, Dublin 2, Irland · **Angaben zu besonderen Warnhinweisen und Vorsichtsmaßnahmen für die Anwendung, Wechselwirkungen mit anderen Arzneimitteln und sonstigen Wechselwirkungen, Fertilität, Schwangerschaft und Stillzeit und Nebenwirkungen sowie möglichen Gewöhnungseffekten entnehmen Sie bitte der veröffentlichten Fachinformation · STAND DER INFORMATION:** Mai 2021. Aufstuhrliehe Informationen zu diesem Arzneimittel sind auf den Internetseiten der Europäischen Arzneimittel-Agentur <http://www.ema.europa.eu> verfügbar.